Prevalence of T3 thyrotoxicosis and it抯 management in new onset thyrotoxicosis patients: a prospective observational study

Simple item page
dc.contributor.authorSingh, SKen_US
dc.contributor.authorSingh, Ren_US
dc.contributor.authorBedi, Sen_US
dc.contributor.authorPandey, AKen_US
dc.contributor.authorTiwari, Aen_US
dc.contributor.authorRai, PKen_US
dc.date.accessioned2025-06-18T11:13:49Z
dc.date.available2025-06-18T11:13:49Z
dc.date.issued2025-02
dc.description.abstractBackground: T3 toxicosis is a subtype of thyrotoxicosis where total triiodothyronine (TT3) level is high but total thyroxine (TT4) level is normal in presence of suppressed thyroid stimulating hormone (TSH). Accurate and rapid diagnosis is crucial in management of T3 toxicosis. Methods: In this prospective observational study from India, newly diagnosed thyrotoxicosis patients were enrolled. T3 toxicosis patients were diagnosed based on diagnostic criteria. T3 toxicosis patients were randomized into two arms, based on dose of carbimazole (CBZ) used for treatment. All patients are following up for 12-14 weeks. Results: Prevalence of T3 toxicosis was 8.5% in this study. 75% were diagnosed as Grave抯 disease (GD) and 25% were diagnosed as toxic nodular goiter (TNG). Low dose (5 mg/day) of CBZ is safer and more effective than higher dose (20 mg/day). Conclusion: Present study suggests that a significant number of patients with thyrotoxicosis are suffering from T3 toxicosis. So, for correct diagnosis of thyrotoxicosis one should investigate for TT3, TT4 and TSH, otherwise we can misdiagnose the T3 toxicosis as subclinical thyrotoxicosis (SCT). Majority of T3 toxicosis patients are diagnosed as GD. Low dose of CBZ is very much effective and safe in these patients. We recommend low dose of CBZ in all patients with T3 toxicosis.en_US
dc.identifier.affiliationsDepartment of Endocrine, Endocrine Clinic, Varanasi, UP, Indiaen_US
dc.identifier.affiliationsDepartment of Endocrine, Endocrine Clinic, Varanasi, UP, Indiaen_US
dc.identifier.affiliationsDepartment of Community Medicine, GMCH, Udaipur, Rajasthan, Indiaen_US
dc.identifier.affiliationsDepartment of Endocrine, LEDTC, Gomtinagar, Lucknow, UP, Indiaen_US
dc.identifier.affiliationsDepartment of Endocrine, DECSC, Varanasi, UP, Indiaen_US
dc.identifier.affiliationsDepartment of Nephrology, Opal Hospital, Varanasi, Indiaen_US
dc.identifier.citationSingh SK, Singh R, Bedi S, Pandey AK, Tiwari A, Rai PK. Prevalence of T3 thyrotoxicosis and it抯 management in new onset thyrotoxicosis patients: a prospective observational study. International Journal of Advances in Medicine. 2025 Feb; 12(1): 39-43en_US
dc.identifier.issn2349-3925
dc.identifier.issn2349-3933
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/248371
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.18203/2349-3933.ijam20243812en_US
dc.subjectT3 toxicosisen_US
dc.subjectGrave's diseaseen_US
dc.subjectCarbimazoleen_US
dc.subjectThyrotoxicosisen_US
dc.titlePrevalence of T3 thyrotoxicosis and it抯 management in new onset thyrotoxicosis patients: a prospective observational studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijam2025v12n1p39.pdf
Size:
181.97 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Advances in Medicine